Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 14/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.69 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.69 |
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 0.66 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.66 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.66 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Codeinone SCHEMBL101725 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1MRGPRX2PDE4D | |
| Codeinone SCHEMBL13952981 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1MRGPRX2PDE4D | |
| Codeinone SCHEMBL13633530 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1MRGPRX2PDE4D | |
| Codeinone SCHEMBL13154678 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1MRGPRX2PDE4D | |
| Codeinone SCHEMBL12137788 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1MRGPRX2PDE4D | |
| Codeinone SCHEMBL100655 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1MRGPRX2PDE4D | |
| Codeinone SCHEMBL14192923 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1MRGPRX2PDE4D | |
| Codeinone SCHEMBL29375985 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1MRGPRX2PDE4D | |
| Codeinone SCHEMBL7707098 | 0.99 | OPRM1 (0.98) | OPRM1OPRK1OPRD1MRGPRX2PDE4D | |
| Codeinone SCHEMBL11533410 | 0.95 | OPRM1 (0.91) | OPRM1OPRK1OPRD1MRGPRX2PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2137189-A2 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | Mallinckrodt Inc. (US) | 2009-12-30 | — | — | EP | claimed |
| EP-1562953-B1 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | MALLINCKRODT INC (US) | 2009-09-30 | — | — | EP | claimed |
| WO-2008109156-A2 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | MALLINCKRODT INC. (US) | 2008-09-12 | — | — | WO | claimed |
| US-7285665-B2 | Process for the preparation of quaternary N-alkyl morphinan alkaloid salts | MALLINCKRODT INC. (US) | 2007-10-23 | — | — | US | claimed |
| US-20060014771-A1 | Process for the preparation of quaternary n-alkyl morphinan alkaloid salts | SpecGx LLC | 2006-01-19 | — | — | US | claimed |
| EP-1562953-A2 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | Mallinckrodt Inc. (US) | 2005-08-17 | — | — | EP | claimed |
| WO-2004043964-A2 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | MALLINCKRODT INC. (US) | 2004-05-27 | — | — | WO | claimed |
| WO-2019109170-A1 | NEOPINONE ISOMERASE AND METHODS OF USING | SERTURNER CORP. (CA) | 2019-06-13 | — | — | WO | disclosed |
| EP-2147920-B1 | Process for the preparation of quaternary n-alkyl morphinan alkaloid salts | MALLINCKRODT LLC (US) | 2016-08-31 | — | — | EP | disclosed |
| US-9415044-B2 | Process for the preparation of quaternary N-alkyl morphinan alkaloid salts | MALLINCKRODT LLC (US) | 2016-08-16 | — | — | US | disclosed |
| US-20150164886-A9 | Process for the Preparation of Quaternary N-Alkyl Morphinan Alkaloid Salts | MALLINCKRODT INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-9040726-B2 | Process for the preparation of quaternary N-alkyl morphinan alkaloid salts | MALLINCKRODT LLC (US) | 2015-05-26 | — | — | US | disclosed |
| US-20150099773-A1 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | VTESSE LLC | 2015-04-09 | — | — | US | disclosed |
| EP-2137189-A2 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | Mallinckrodt Inc. (US) | 2009-12-30 | — | — | EP | disclosed |
| EP-1562953-B1 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | MALLINCKRODT INC (US) | 2009-09-30 | — | — | EP | disclosed |
| WO-2008109156-A2 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | MALLINCKRODT INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| US-7285665-B2 | Process for the preparation of quaternary N-alkyl morphinan alkaloid salts | MALLINCKRODT INC. (US) | 2007-10-23 | — | — | US | disclosed |
| US-20060014771-A1 | Process for the preparation of quaternary n-alkyl morphinan alkaloid salts | SpecGx LLC | 2006-01-19 | — | — | US | disclosed |
| EP-1562953-A2 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | Mallinckrodt Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004043964-A2 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | MALLINCKRODT INC. (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014771-A1 | Process for the preparation of quaternary n-alkyl morphinan alkaloid salts | TTN, PML, EMD | OPRM1 45/4885OPRK1 245/4885OPRD1 164/4885 |
| US-20150099773-A1 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | RAN, RANBP1, NCLN | OPRM1 60/4885OPRK1 527/4885OPRD1 406/4885 |
| US-20150164886-A9 | Process for the Preparation of Quaternary N-Alkyl Morphinan Alkaloid Salts | RAN, RANBP1, NCLN | OPRM1 60/4885OPRK1 527/4885OPRD1 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.